US pharma giant Merck & Co (NYSE: MRK) on Tuesday raised its outlook for full-year profit while posting a second-quarter earnings ahead of estimates despite a drop in sales.
The company reported second-quarter earnings down over 65% at $687 million, or $0.24 a share, against $2 billion, or $0.68 a share a year earlier. Overall, sales dropped 11% to $9.79 billion.
The drugmaker raised its full-year adjusted earnings target to $3.45 to $3.55 a share, from $3.35 to $3.48 a share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze